Elizabeth is co-Founder and Managing Partner of AmorChem. As a co-founder, she played an important role in elaborating the innovative early-stage investment model of AmorChem, as well as setting up and supervising its operations. Her strategic input and vision have been critical in the fund’s success. She oversaw the investment in nine of the funds promising technologies and in 2016, successfully created AmorChem’s first spin out company, Mperia Therapeutics. Since then, she spearheaded the efforts to create two more companies, Corbin Therapeutics and Fairhaven Pharmaceuticals. Subsequent to closing the AmorChem II fund, she led the fund’s first investment in a Montreal-based start-up, Inversago Pharma. She is a sought-after participant in the life sciences ecosystem and sits on the board of several organisations such as Genome Canada and BioCanRx. She is also a member of the Canada Foundation for Innovation.
Elizabeth started her venture capital career by joining the GeneChem family of funds in 1997, rising rapidly from Manager to General Partner. She obtained a PhD in biochemistry from the University of Ottawa and a post-doctoral fellowship from the Imperial Cancer Research Fund in London, UK. She also completed a management certificate offered by CIREM/University of Montreal.